Table 4. Multivariable linear mixed effects analysis of heart rate after antimalarial treatment in adolescents and adults (age ≥12 years).
| Variable | Number of observations | Adjusted estimate (95% CI) | p-value |
|---|---|---|---|
| Change from baseline after ASAQ | 689 | −15.17 (−16.98 to −13.35) beats/minute | <0.001 |
| Change from baseline versus ASAQ, by antimalarial treatment arm | 2,041 | ||
| ASAQ | 689 | Reference | |
| CQ | 345 | 9.30 (6.63 to 11.98) beats/minute | <0.001 |
| DP | 298 | 4.64 (1.82 to 7.45) beats/minute | 0.0013 |
| AL | 328 | 5.86 (2.99 to 8.73) beats/minute | <0.001 |
| PA | 381 | 8.54 (5.94 to 11.13) beats/minute | <0.001 |
| Baseline measurement versus ASAQ, by antimalarial treatment arm | 1,096 | ||
| ASAQ | 384 | Reference | |
| CQ | 172 | −0.75 (−3.40 to 1.91) beats/minute | 0.5816 |
| DP | 149 | −0.07 (−3.12 to 2.97) beats/minute | 0.9620 |
| AL | 200 | −0.41 (−3.14 to 2.31) beats/minute | 0.7672 |
| PA | 191 | −2.23 (−5.20 to 0.74) beats/minute | 0.1408 |
| Body temperature, per 1°C increase | 2,041 | 8.14 (7.54 to 8.73) beats/minute | <0.001 |
| Sex | 2,041 | ||
| Female | 829 | Reference | |
| Male | 1,212 | −7.84 (−9.27 to −6.41) beats/minute | <0.001 |
AL, artemether–lumefantrine; ASAQ, artesunate–amodiaquine; CQ, chloroquine; DP, dihydroartemisinin–piperaquine; PA, pyronaridine–artesunate.